Remove 2023 Remove FDA Remove Medical science
article thumbnail

Novaliq’s dry eye disease therapy receives US FDA approval

Pharmaceutical Technology

Biopharmaceutical company Novaliq has received approval from the US Food and Drug Administration (FDA) for VEVYE (cyclosporine ophthalmic solution) 0.1% Novaliq medical science and regulatory affairs vice-president Sonja Krösser stated: “We are proud that the FDA approved VEVYE.

article thumbnail

Reducing real world data lag time for improved patient outcomes

Clarivate

In recent years, there has been an increased focus on real world evidence to advance medical science and improve patient quality of life. The suitability of RWD, the FDA said in a 2017 guidance report , depends on its relevance (whether data directly addresses intended use) and reliability (completeness, accuracy and timeliness) [2].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Manufacturing challenges set back development progress of cell therapies in oncology

Pharmaceutical Technology

Meanwhile, the drug's closest TIL competitor, Iovance Biotherapeutics’ lifileucel, has begun a rolling BLA for advanced melanoma patients and could reach the market as early as Q3 2023. In April this year, the FDA provided new feedback on the potency assays, which Iovance indicated will be addressed in the latest BLA.

article thumbnail

Leveraging innate cell engagers for lymphoma treatment

European Pharmaceutical Review

We received encouraging feedback from the US Food and Drug Administration (FDA) on the trial design and potential for accelerated approval. Can you share some highlights from the data presented at ASH 2023? The IND for the combination was cleared in May 2023 and we have now treated patients in the first two cohorts.

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. This trial is anticipated to begin in the second half of 2023. Biologics Global Market Report 2023. 2023 [cited 2023Feb]. References Urquhart L. Top companies and drugs by sales in 2021. 2022;21(4):251–.

article thumbnail

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Medgadget

The FDA looked at the data, saw it promising, and asked for a small feasibility study in the U.S. This will hopefully lead to an FDA approval for its first indication, after which Alpha TAU plans on expanding to other types of cancer and geographic regions such as Europe and Japan. The rest of the patients had partial responses.

article thumbnail

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Medgadget

Interestingly, due to FDA’s regulatory methodology, surgical robots have to be approved for specific indications by the agency. Here’s an excellent video of the HandX used in clinical practice: Product page: Human Xtensions HandX… Biomed Israel , is the leading international Life Science and HealthTech conference in Israel.